Q-omics provides the consensus-scored CADM2 profile across patient tissues and cancer cell-line models. CADM2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CADM2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, CADM2 protein abundance shows 14,965 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, COAD, and GBM as cancer lineages where CADM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CADM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CADM2 survival associations across molecular data types. CADM2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CADM2 RNA expression–survival associations across cancer types. High CADM2 expression shows unfavorable associations in ACC, UCEC, KIRP and KIRC, but favorable associations in BRCA and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for CADM2 RNA expression.
This table summarizes CADM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CADM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CADM2 shows lower tumor expression in COAD, KIRC, BLCA, STAD, THCA and HNSC. The COAD box plot shows higher CADM2 RNA expression in normal versus tumor tissue (log2 FC = −0.920, t-test p < 0.001).
This table shows molecular features associated with CADM2 in patient tissues and cancer cell lines. In patient samples, CADM2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CADM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
